For example, decreases in miR-133a have been linked to increases in RhoA pathway activity in bronchiolar smooth muscle and airway hyperresponsiveness due to IL-13 or IL-17 treatment31,32. This evidence concerns the gene IL13 and airway hyperresponsiveness.